Lyra Therapeutics raises $29.5M for chronic rhinosinusitis drug implant
The company plans to use the funding to advance LYR-210 into a Phase II clinical trial and also explore its development platform in other ENT diseases.
LYR-210
The company plans to use the funding to advance LYR-210 into a Phase II clinical trial and also explore its development platform in other ENT diseases.